Picankibart API is a recombinant monoclonal antibody designed to selectively target the p19 subunit of interleukin-23 (IL-23p19). Also identified by its development code IBI-112, Picankibart is a humanized/human-derived IgG1-kappa monoclonal antibody engineered for prolonged activity and is being developed for immune-mediated inflammatory diseases. It specifically binds IL-23p19 and inhibits IL-23-mediated signaling pathways involved in inflammatory and autoimmune responses.
Picankibart is a biological API rather than a conventional small-molecule pharmaceutical ingredient. Consequently, its quality evaluation requires biologics-focused analytical characterization, including identity, purity, molecular-size distribution, aggregation, charge variants, potency, protein concentration, host-cell-related impurities, residual process components, and microbial or endotoxin controls. These parameters are fundamentally different from the fixed chemical specifications commonly applied to small-molecule APIs.
The API is associated with CAS No. 2622900-74-5 and has a reported molecular weight of approximately 144.744 kDa in commercial research references. Because Picankibart is a recombinant antibody, it does not have a conventional small-molecule molecular formula that can be meaningfully represented in the same manner as compounds such as tablets or chemical APIs.
Picankibart selectively targets the IL-23p19 subunit, preventing IL-23 from interacting with its cell-surface receptor. Inhibition of this pathway reduces downstream inflammatory signaling, including pathways associated with STAT3 activation and IL-17 production. This mechanism makes Picankibart relevant to the development of targeted biologic therapies for chronic inflammatory diseases.
Clinical development has particularly focused on moderate-to-severe plaque psoriasis. The Phase III CLEAR-1 study evaluated Picankibart in adults with moderate-to-severe plaque psoriasis, including dosing regimens designed around extended maintenance intervals. The published Phase III results describe Picankibart as an IL-23p19 inhibitor and evaluate its efficacy and safety in this patient population.
Picankibart has also been investigated in other immune-mediated conditions. Innovent reported Phase II clinical development in moderately to severely active ulcerative colitis, while additional clinical studies have evaluated or continue to evaluate its potential in conditions including psoriatic arthritis.
Manufacturing Picankibart API requires a controlled recombinant-biologic production process. Unlike a traditional chemical API, production involves biological expression, purification, viral and microbial control strategies, and extensive characterization of the resulting antibody. Consistency between manufacturing batches is particularly important because monoclonal antibodies can be affected by structural modifications, aggregation, charge heterogeneity and other product-quality attributes.
Analytical testing for Picankibart may include SEC-HPLC or SEC-based analysis for size variants and aggregates, chromatographic methods for purity and charge characteristics, peptide mapping or mass spectrometry for identity and structural characterization, SDS-PAGE, protein concentration testing, binding assays and cell-based potency assays. Research-grade references also report analytical documentation including SEC-HPLC, LC-MS and SDS-PAGE for Picankibart characterization.
Because there is no conventional pharmacopoeial small-molecule assay range such as 98–102% applicable to Picankibart in the sources reviewed, numerical release specifications should not be invented or transferred from unrelated monoclonal antibodies. For commercial pharmaceutical manufacture, final acceptance criteria should be established against the applicable regulatory dossier, validated analytical procedures and batch-specific Certificate of Analysis.
Picankibart is currently relevant to the IL-23-targeted biologics segment, particularly for psoriasis research and pharmaceutical development. China's NMPA approved Picankibart injection, marketed as PECONDLE, in November 2025 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Innovent describes it as a recombinant anti-IL-23p19 monoclonal antibody with an engineered Fc region intended to extend its half-life.
For pharmaceutical companies, research organizations and biologics developers evaluating Picankibart API, important considerations include molecular identity, antibody integrity, purity, aggregation profile, potency, biological activity, endotoxin, bioburden, host-cell protein, residual DNA, process-related impurities and stability. Appropriate cold-chain handling and storage conditions are also essential for maintaining biologic quality; commercial research references recommend low-temperature storage, with exact conditions determined by the product's lot-specific documentation.
Overall, Picankibart represents an important next-generation IL-23p19 monoclonal antibody API with established clinical development and regulatory significance. Its biologic nature means that API procurement and quality assessment should focus on comprehensive biological characterization rather than conventional chemical purity alone.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |